Galasko DR - Search Results

1

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative. Kang JH, et al. Among authors: galasko dr. Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28. Acta Neuropathol. 2016. PMID: 27021906 Free PMC article.

2

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Galasko D, et al. Neurology. 1997 Mar;48(3):632-5. doi: 10.1212/wnl.48.3.632. Neurology. 1997. PMID: 9065538 Clinical Trial.

3

CSF tau and Abeta42: logical biomarkers for Alzheimer's disease?

Galasko D. Galasko D. Neurobiol Aging. 1998 Mar-Apr;19(2):117-9. doi: 10.1016/s0197-4580(98)00021-9. Neurobiol Aging. 1998. PMID: 9558144 No abstract available.

4

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Galasko D, et al. Arch Neurol. 1998 Jul;55(7):937-45. doi: 10.1001/archneur.55.7.937. Arch Neurol. 1998. PMID: 9678311 Clinical Trial.

5

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

Galasko D. Galasko D. J Neural Transm Suppl. 1998;53:209-21. J Neural Transm Suppl. 1998. PMID: 9700659 Review.

6

Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia.

Zhukareva V, Vogelsberg-Ragaglia V, Van Deerlin VM, Bruce J, Shuck T, Grossman M, Clark CM, Arnold SE, Masliah E, Galasko D, Trojanowski JQ, Lee VM. Zhukareva V, et al. Ann Neurol. 2001 Feb;49(2):165-75. doi: 10.1002/1531-8249(20010201)49:2<165::aid-ana36>3.0.co;2-3. Ann Neurol. 2001. PMID: 11220736

7

Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. Rockenstein E, et al. Brain Res. 2001 Sep 28;914(1-2):48-56. doi: 10.1016/s0006-8993(01)02772-x. Brain Res. 2001. PMID: 11578596

8

Biological markers and the treatment of Alzheimer's disease.

Galasko D. Galasko D. J Mol Neurosci. 2001 Oct;17(2):119-25. doi: 10.1385/JMN:17:2:119. J Mol Neurosci. 2001. PMID: 11816785 Review.

9

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, Rogers J, Siemers E, Trojanowski JQ; National Institute on Aging Biological Markers Working Group. Frank RA, et al. Neurobiol Aging. 2003 Jul-Aug;24(4):521-36. doi: 10.1016/s0197-4580(03)00002-2. Neurobiol Aging. 2003. PMID: 12714109 Review. No abstract available.

10

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Clark CM, et al. Arch Neurol. 2003 Dec;60(12):1696-702. doi: 10.1001/archneur.60.12.1696. Arch Neurol. 2003. PMID: 14676043

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

467 results

Search Page